Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 20, 2011, Pages 8414-8419

  Liu, Ning Ai ^a   Jiang, Hong ^a   Ben Shlomo, Anat ^a   Wawrowsky, Kolja ^a   Fan, Xue Mo ^a   Lin, Shuo ^b   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adrenal function; Pituitary cell cycle; Pituitary hormone

Indexed keywords

BETA ACTIN; CORTICOSTERONE; CORTICOTROPIN; CYCLIN E; GLUCOCORTICOID; PROOPIOMELANOCORTIN; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P57; ROSCOVITINE;

ACTH SECRETING ADENOMA; ADENOHYPOPHYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; CUSHING DISEASE; DOWN REGULATION; EMBRYO; EMBRYO DEVELOPMENT; FEMALE; GENE; GENE OVEREXPRESSION; HYPERCORTISOLISM; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PTTG GENE; SENESCENCE; TRANSGENIC ANIMAL; TUMOR GROWTH; UPREGULATION; VALIDATION PROCESS; ZEBRA FISH;

ACTH-SECRETING PITUITARY ADENOMA; ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; CORTICOSTERONE; CYCLIN E; CYCLIN-DEPENDENT KINASES; GENE EXPRESSION REGULATION; MICE; PITUITARY ACTH HYPERSECRETION; PURINES; ZEBRAFISH;

DANIO RERIO; MURINAE;

EID: 79957698082     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1018091108     Document Type: Article

References (40)

1. Nieman LK, et al. (2008) The diagnosis of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526-1540. (Pubitemid 351656485)
2. Biller BM, et al. (2008) Treatment of adrenocorticotropin-dependent Cushing's syndrome: A consensus statement. J Clin Endocrinol Metab 93:2454-2462. (Pubitemid 352008503)
3. Assié G, et al. (2007) Corticotroph tumor progression after adrenalectomy in Cushing's disease: A reappraisal of Nelson's syndrome. J Clin Endocrinol Metab 92:172-179. (Pubitemid 46067527)
4. Boscaro M, et al. (2009) Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): A multicenter, phase II trial. J Clin Endocrinol Metab 94:115-122.
5. Melmed S (2003) Mechanisms for pituitary tumorigenesis: The plastic pituitary. J Clin Invest 112:1603-1618.
6. Moons DS, et al. (2002) Pituitary hypoplasia and lactotroph dysfunction in mice deficient for cyclin-dependent kinase-4. Endocrinology 143:3001-3008. (Pubitemid 34809873)
7. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189-3202.
8. Sotillo R, et al. (2005) Cooperation between Cdk4 and p27kip1 in tumor development: A preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res 65:3846-3852. (Pubitemid 40616365)
9. Roussel-Gervais A, et al. (2010) Cooperation between cyclin E and p27Kip1 in pituitary tumorigenesis. Mol Endocrinol 24:1835-1845.
10. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 9:153-166.
11. Fabian MA, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336. (Pubitemid 41094421)
12. Vlotides G, Eigler T, Melmed S (2007) Pituitary tumor-transforming gene: Physiology and implications for tumorigenesis. Endocr Rev 28:165-186. (Pubitemid 46984833)
13. Pei L, Melmed S (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11:433-441. (Pubitemid 27147011)
14. Marangos P, Carroll J (2008) Securin regulates entry into M-phase by modulating the stability of cyclin B. Nat Cell Biol 10:445-451.
15. Romero F, et al. (2001) Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res 29: 1300-1307. (Pubitemid 32229457)
16. Tong Y, Tan Y, Zhou C, Melmed S (2007) Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene 26:5596-5605. (Pubitemid 47267833)
17. Zou H, McGarry TJ, Bernal T, KirschnerMW (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285:418-422.
18. Bernal JA, et al. (2008) Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin. Cell Death Differ 15:202-212. (Pubitemid 350286188)
19. Kim D, et al. (2005) Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene 24:4861-4866. (Pubitemid 41076304)
20. Chesnokova V, et al. (2008) p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA 105:17498-17503.
21. Donangelo I, et al. (2006) Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology 147:4781-4791. (Pubitemid 44402185)
22. Liu NA, et al. (2003) Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. Mol Endocrinol 17:959-966.
23. Camper SA, Saunders TL, Katz RW, Reeves RH (1990) The Pit-1 transcription factor gene is a candidate for the murine Snell dwarf mutation. Genomics 8:586-590.
24. Lamolet B, et al. (2001) A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 104:849-859. (Pubitemid 32289278)
25. Liu J, et al. (2001) Tbx19, a tissue-selective regulator of POMC gene expression. Proc Natl Acad Sci USA 98:8674-8679. (Pubitemid 32678086)
26. Bilodeau S, et al. (2006) Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 20:2871-2886. (Pubitemid 44771748)
27. Hsu HJ, Lin G, Chung BC (2003) Parallel early development of zebrafish interrenal glands and pronephros: Differential control by wt1 and ff1b. Development 130:2107-2116. (Pubitemid 36656707)
28. Alexander EL, Dooley KC, Pohajdak B, Xu BY, Wright JR, Jr. (2006) Things we have learned from tilapia islet xenotransplantation. Gen Comp Endocrinol 148:125-131. (Pubitemid 44142496)
29. Muiesan ML, et al. (2003) Left ventricular structural and functional characteristics in Cushing's syndrome. J Am Coll Cardiol 41:2275-2279. (Pubitemid 36724279)
30. Iida H, et al. (1997) Overexpression of cyclin E in acute myelogenous leukemia. Blood 90:3707-3713.
31. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB (2000) Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 143:R1-R6. (Pubitemid 30482213)
32. De Azevedo WF, et al. (1997) Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243:518-526. (Pubitemid 27060442)
33. Montagnoli A, et al. (2008) A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol 4:357-365. (Pubitemid 351693995)
34. Liu NA, et al. (2006) Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotrophs. Mol Endocrinol 20:871-880.
35. Bilodeau S, Roussel-Gervais A, Drouin J (2009) Distinct developmental roles of cell cycle inhibitors p57Kip2 and p27Kip1 distinguish pituitary progenitor cell cycle exit from cell cycle reentry of differentiated cells. Mol Cell Biol 29:1895-1908.
36. De Martino I, et al. (2009) HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res 69:1844-1850.
37. Quereda V, Malumbres M (2009) Cell cycle control of pituitary development and disease. J Mol Endocrinol 42:75-86.
38. Whittaker SR, Walton MI, Garrett MD, Workman P (2004) The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates themitogen-activated protein kinase pathway. Cancer Res 64:262-272. (Pubitemid 38114107)
39. McClue SJ, et al. (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102:463-468.
40. Legraverend M, Grierson DS (2006) The purines: Potent and versatile small molecule inhibitors and modulators of key biological targets. Bioorg Med Chem 14: 3987-4006. (Pubitemid 44287808)